|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
|
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 3, 2025
Vivani Medical, Inc.
(Exact name of Registrant as Specified in Its Charter)
|
Delaware
|
|
001-36747
|
|
02-0692322
|
|
(State or Other Jurisdiction of
Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
1350 S. Loop Road
Alameda, California 94502
(Address of principal executive offices, including zip code)
(415) 506-8462
(Telephone number, including area code, of agent for service)
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
|
Common Stock, par value $0.0001 per share
|
|
VANI
|
|
The Nasdaq Capital Market
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01
Regulation FD Disclosure.
On October 3,
2025, Vivani Medical, Inc. (the “Company”) issued a press release titled “Vivani
Medical Withdraws Record Date for Cortigent Neuromodulation Subsidiary Spin-Off.”
A copy of the press release is attached as Exhibit 99.1 hereto.
The information
set forth under Item 7.01 and in Exhibit 99.1 is intended to be furnished and
shall not be deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to
the liabilities of that section, nor shall it be deemed incorporated by
reference in any filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as shall be expressly set forth by specific reference in
such filing.
Item 8.01
Other Events.
Withdrawal of Record
Date for Cortigent Spin-off
On October 3,
2025, the Company announced that it is temporarily withdrawing the previously-announced
record date of October 8, 2025 for the proposed spinoff of its wholly-owned
subsidiary, Cortigent, Inc., which is developing brain implant devices with
cutting-edge neuromodulation technology, due to delays arising from the current
shutdown of the U.S. federal government.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. |
Description |
| 99.1 |
|
Press release issued by Vivani Medical, Inc. on October 3, 2025.
|
| 104 |
|
Cover Page Interactive Data
File (embedded within the Inline XBRL document).
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
VIVANI MEDICAL, INC.
|
|
|
|
|
|
Date:
October 3, 2025
|
By:
|
/s/ Donald Dwyer
|
|
|
Name:
|
Donald Dwyer
|
|
|
Title:
|
Chief Business Officer
|
